Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vosevi with or without Ribavirin in DAA-experienced Genotype 1 HCV
NCT02536313Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Jul 2015
- Primary completion
- Mar 2016
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sofosbuvir + velpatasvir + voxilaprevir in hepatitis C virus infection, sponsored by Gilead Sciences. Started Jul 2015; status: completed.
02
Drugs
sofosbuvir + velpatasvir + voxilaprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT02536313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02536313.